Results 111 to 120 of about 30,099 (284)

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Microwave Assisted Organic Synthesis (MAOS) of Small Molecules as Potential HIV-1 Integrase Inhibitors

Molecules, 2011
Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). In recent years our research group has been engaged in the stucture-function study of this enzyme and in the development
Alba Chimirri, Caterina Elisa Faliti, Zeger Debyzer, Rosaria Gitto, Laura De Luca, Sara De Grazia, Stefania Ferro   +6 more
doaj   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source

Genetic diversity and baseline drug resistance of South African HIV-1 Integrase sequences prior to the availability of Integrase strand-transfer inhibitors [PDF]

, 2020
Dominik Brado
openalex   +1 more source

Frequency of Major Transmitted Integrase Resistance in Poland Remains Low Despite Change in Subtype Variability

Viruses
With the widespread use of integrase inhibitors and the expanding use of long-acting cabotegravir in both pre-exposure prophylaxis and antiretroviral treatment, molecular surveillance on the transmission of integrase resistance has regained clinical ...
Kaja Mielczak, Karol Serwin, Anna Urbańska, Bogusz Aksak-Wąs, Malwina Karasińska-Cieślak, Elżbieta Mularska, Adam Witor, Paweł Jakubowski, Maria Hlebowicz, Monika Bociąga-Jasik, Elżbieta Jabłonowska, Aleksandra Szymczak, Bartosz Szetela, Władysław Łojewski, Miłosz Parczewski   +14 more
doaj   +1 more source

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source

Design, Synthesis and Anti-HIV Integrase Evaluation of N-(5-Chloro-8-Hydroxy-2-Styrylquinolin-7-yl)Benzenesulfonamide Derivatives

Molecules, 2010
Styrylquinoline derivatives are demonstrated to be HIV-1 integrase inhibitors. On the basis of our previous CoMFA analysis of a series of styrylquinoline derivatives, N-[(2-substituted-styryl)-5-chloro-8-hydroxyquinolin-7-yl]-benzenesulfonamide ...
Li-Ming Hu, Jian-Jun Tan, Cheng-Chu Zeng, Hong-Qiu He, Zi-Guo Jiao, Cun-Xin Wang   +5 more
doaj   +1 more source

Frailty Transition Among Older Adults Living With HIV in Thailand: A 5‐Year Longitudinal Study

Journal of the International AIDS Society, Volume 29, Issue 4, April 2026.
ABSTRACT Introduction Frailty is highly prevalent among older people with HIV (PWH), driven by multimorbidity and HIV‐associated accelerated ageing. We investigated frailty transitions and associated factors over a 5‐year follow‐up period in an ageing cohort of PWH in Thailand. Methods We conducted a prospective cohort study among PWH aged ≥50 years in
Tanakorn Apornpong, Win Min Han, Akarin Hiransuthikul, Hay Mar Su Lwin, Napon Hiranburana, Sasiwimol Ubolyam, Stephen J. Kerr, Thira Woratanarat, Anchalee Avihingsanon, HIV‐NAT 006 and 207 study team   +9 more
wiley   +1 more source

First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. [PDF]

Biochem Biophys Rep, 2022
Ghasabi F, Hashempour A, Khodadad N, Bemani S, Keshani P, Shekiba MJ, Hasanshahi Z.   +6 more
europepmc   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A, Deming, Timothy, Elliott, Julie, Fulcher, Jennifer A, Ibarrondo, F Javier, Kickhoefer, Valerie A, Maynard, Heather D, Mrazek, Jan, Rome, Leonard H, Tamshen, Kyle, Wollenberg, Alexander L, Yang, Otto O   +11 more
core